This website uses first-party and third-party cookies to enhance our services and show you information related to your preferences by analysing your browsing habits. By continuing to browse our website you accept our use of cookies. You can change the settings or get more information by visiting our Cookies Policy.

European Approval as a class IIa medical device:

  • APROTECOL® is intended to the treatment of meteorism, aerophagy and flatulent colics in infants, children and adults. The film-forming agent contained in APROTECOL® contributes to reduce the interaction of intestinal pathogens with the mucus membrane and their subsequent proliferation, thus preventing the rise of altered biologic responses which may provoke the increase of the gas content in the intestine. The presence of tyndallized lactobacillus reuterii and Bifidobacterium Brevis contributes to the prevention of pathogenic bacterial invasion.

  • APROTECOL® is available in drops.



       
This area contains information intended exclusively for health professionals authorized to prescribe or dispense pharmaceutical products.
   
Calle Consejo de Ciento, 333
08007 Barcelona, Spain

Contact us

info@noventure.com
NOVENTURE S.L.
Tel: +34.93.205.27.18